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Abstract A novel inhibitor of voltage-gated potassium channel
was isolated and puri¢ed to homogeneity from the venom of the
red scorpion Buthus tamulus. The primary sequence of this tox-
in, named BTK-2, as determined by peptide sequencing shows
that it has 32 amino acid residues with six conserved cysteines.
The molecular weight of the toxin was found to be 3452 Da. It
was found to block the human potassium channel hKv1.1
(IC50 = 4.6 WM). BTK-2 shows 40^70% sequence similarity to
the family of the short-chain toxins that speci¢cally block po-
tassium channels. Multiple sequence alignment helps to catego-
rize the toxin in the ninth subfamily of the K+ channel blockers.
The modeled structure of BTK-2 shows an K/L sca¡old similar
to those of the other short scorpion toxins. Comparative anal-
ysis of the structure with those of the other toxins helps to
identify the possible structure^function relationship that leads
to the di¡erence in the speci¢city of BTK-2 from that of the
other scorpion toxins. The toxin can also be used to study the
assembly of the hKv1.1 channel.
6 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Scorpion venom consists of a large number of toxins, which
act as blockers of ion channels, showing neurotoxic e¡ects.
This tool has long been used by the biologists to unravel the
structure of ion channels such as Kþ and Naþ. The determi-
nation of the tetrameric structure of the Kþ channels [1] and
the identi¢cation of their pore region [2] were made possible
by the use of scorpion toxins. These small peptide inhibitors
thus help in the characterization of ion channels structurally
as well as pharmacologically. The binding studies of these
inhibitors with ion channels further provide an insight into
the speci¢city of these toxins towards di¡erent ion channels.
In addition, these peptides have been valuable tools for under-
standing the physiological role of speci¢c channel proteins [3].
The scorpion toxins are divided into two classes. The long-
chain scorpion toxins consist of 60^70 amino acid residues
compacted by four disul¢de bonds. Their targets are the vol-
tage-sensitive Naþ channels of excitable nerve and muscle
cells and they can be classi¢ed into K-toxins, which slow
down Naþ channel inactivation [4] and L-toxins, which a¡ect
the channel activation process [5]. Short-chain scorpion toxins
contain up to 40 amino acid residues with three or four di-
sul¢de bridges, and have a⁄nity towards the Kþ and Cl3
channels [6]. These two classes of toxins share a common
structural framework consisting of a double-stranded antipar-
allel L-sheet linked to a short K-helix. Insect defensins pro-
duced by the insects in response to body injury or bacterial
infection [7] and the plant Q-thionines [8] also possess a similar
kind of structural con¢guration.
The short toxins a¡ecting potassium channels have been
divided into three structurally distinct groups, designated as
K-KTx [9], L-KTx [6] and Q-KTx [10]. The peptides belonging
to the K-KTx are the best studied. They block the potassium
channel by physically occluding the pore of the channel [3].
Toxins speci¢c to potassium channels show a common
structural motif with one K-helix and two to three antiparallel
L-strands forming a L-sheet structure, compacted with three to
four disul¢de bonds [11]. In spite of the similar K/L sca¡old
there are variations among these toxins in the size of the
L-sheet, the type of L-turns and the type of the helix. These
di¡erences in structure lead to variations in the speci¢city of
the toxins towards di¡erent ion channels [12]. Binding studies
on mutants of charybdotoxin indicated the signi¢cance of
‘crucial’ residues that participate in the toxin^ion channel in-
teractions. The most crucial residue Lys27 has been found to
occlude the pore of the potassium channel [13].
We have puri¢ed a novel peptide from the venom of the red
Indian scorpion Buthus tamulus. An attempt has been made to
characterize this peptide structurally as well as functionally by
the determination of the primary structure, mass spectrometry
and electrophysiological studies. BTK-2 isolated from B. ta-
mulus was found to show highest similarity to the ninth sub-
family of the K-KTx group of potassium channel inhibitors
[9]. This toxin blocks the human voltage-gated Kþ channel,
hKv1.1.
2. Materials and methods
2.1. Material
Venom of the scorpion B. tamulus was obtained in a lyophilized
state from the Ha¡kine Institute, Parel, Mumbai, India. All solvents
used for separation were of high-performance liquid chromatography
(HPLC) grade obtained from Spectrochem (India). The chemicals
used for sequencing were purchased from Wako (Japan). Bovine se-
rum albumin (BSA) used as a standard for protein assay was obtained
from SRL (India). All chemicals used for preparation of bu¡ers were
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of analytical grade. Bu¡ers were ¢ltered through 0.45 Wm ¢lters (Sar-
torius, USA). The crude venom was ¢ltered using 0.2 Wm ¢lters (Pall
Gelman Labs, USA). Amino acid sequencing was done on a gas phase
sequencer (PPSQ-10) from Shimadzu, consisting of a HPLC system
with a reverse-phase C18 column (4.6U250 mm) and a SPD-10 UV
detector. Absorbance was measured on an UV-265 spectrophotometer
from Shimadzu. Centrifugation was done in Beckman’s J2-21M/E
using J-18 rotor. A strong cation exchange column, Resource S
(1 ml) (6.4U30 mm) from Pharmacia was used for ion exchange
chromatography and reverse-phase HPLC was done on C4 and C18
semi-preparative columns (22U250 mm) from Vydac. Puri¢ed frac-
tions were lyophilized in the speed vac concentrator from Savant.
2.2. Puri¢cation
115 mg of crude venom of B. tamulus obtained in the lyophilized
form was weighed and dissolved in 20 ml of water and stirred at 4‡C
for 4 h. The solution was centrifuged at 13 300Ug at 4‡C for 20 min
to separate the mucous material of the venom. The clear supernatant
was separated and the pellet was resuspended in 20 ml water and
stirred for 4 h and again centrifuged. The supernatants were pooled
and ¢ltered through a 0.2 Wm ¢lter and then lyophilized in a speed vac
concentrator. The ¢ltered water extract of the venom was used for
further puri¢cation. The crude venom after processing was applied on
a Resource S (Pharmacia 6.4U30 mm) cation exchange HPLC col-
umn, equilibrated with 20 mM sodium acetate bu¡er, pH 5. Separa-
tion was performed using a linear gradient of 0^100% of 0.5 M NaCl
added to 20 mM sodium acetate bu¡er, pH 5, at a £ow rate of 0.5 ml/
min. The fractions were collected manually according to the absor-
bance. The fraction eluting at retention time 20^23 min was collected,
lyophilized in the speed vac concentrator, and applied on a C4
(22U250 mm, Vydac) semipreparative reverse-phase HPLC column,
equilibrated with 0.1% of tri£uoroacetic acid (TFA) in water. Sepa-
ration was done using a linear gradient of 0.1% TFA in acetonitrile
starting from 15% for the ¢rst 5 min, then increasing from 15 to 60%
in the next 45 min with a £ow rate of 2.5 ml/min. The absorbance was
measured at 215 nm as well as 280 nm. The manually collected frac-
tions were again lyophilized and applied on a C18 (22U250 mm,
Vydac) semipreparative reverse-phase HPLC column. Separation
was performed using a gradient starting from 15% of 0.1% TFA in
acetonitrile for the ¢rst 5 min and then going from 15% to 31% in the
next 20 min, with a £ow rate of 2.5 ml/min. The ¢nal fraction ob-
tained was denoted as BTK-2, which was lyophilized and the amount
of protein estimated by the method of Lowry et al. [14].
2.3. Mass spectroscopy
The purity and molecular weight of the components isolated and
fractionated from the crude venom were assessed by electrospray ion-
ization mass spectrometry (ESI-MS). The ESI-MS spectra were re-
corded on a Hewlett-Packard (model HP-1100) electrospray mass
spectrometer. The mass spectra corresponding to each peak present
in the total ion current (TIC) chromatograms were averaged to de-
termine the molecular masses accurately.
2.4. Amino acid sequencing
The disul¢de bonds of BTK-2 were simultaneously reduced and
alkylated by adding tri-n-butyl phosphine and 4-vinylpyridine. The
position of the cysteines was identi¢ed by immobilizing the toxin on
Immobilon-PSQ polyvinylidene di£uoride membrane (Millipore) and
5 Wl of the mixture of 0.6% tri-n-butylphosphine and 1.2 Wl of 4-vinyl-
pyridine in 80% isopropanol was added for the simultaneous reduc-
tion and alkylation of the toxin, followed by Edman degradation
reaction. The reaction was performed at 60‡C for 50 min. The N-ter-
minal amino acid sequence analysis of the native and the reduced and
pyridylethylated toxin was performed on PPSQ-10 sequencer.
2.5. Electrophysiological experiments
Stage V and VI oocytes were isolated by mini-laparotomy from
adult female Xenopus laevis. The frogs were anesthetized by immer-
sion in 0.04% benzocaine for 15^20 min, and then placed on a wet
platform during dissection and removal of ovarian lobes. The incision
was suture-closed and the frog was allowed to recover for about
2 months before removal of another batch of oocytes. Clusters of
oocytes were treated with 1 mg/ml Type 1A collagenase (Sigma) in
OR-Mg solution that contained (mM): 82 NaCl, 2 KCl, 20 MgCl2,
5 HEPES (pH 7.7). The isolated oocytes were then incubated for
microinjection at 18‡C in ND96-HS solution containing (mM): 96
NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, 2.5 Na-pyruvate (pH
7.7) supplemented with 100 U/ml of Pen-Strep and 5% heat-inacti-
vated horse serum.
Capped polyadenylated RNA of hKv1.1 was generated using T7
RNA Polymerase (mMessage mMachine transcription kit, Ambion,
USA). 46 nl of transcribed RNA (150^300 ng/Wl) was injected per
oocyte. Electrophysiological recordings were carried out 2^5 days
after microinjection. Methods for cRNA injection and two-electrode
voltage clamp of Xenopus oocytes have been described in [15]. In
short, we used an OC-725 oocyte clamp ampli¢er (Warner Instru-
ments) to maintain the holding potentials and record membrane cur-
rents. The external recording solution was modi¢ed ND96, containing
(mM): 96 sodium gluconate, 2 potassium gluconate, 1.8 calcium glu-
conate, 1 magnesium gluconate, 5 HEPES (pH 7.7). Solution ex-
change was achieved by gravity £ow. Analog data from the ampli¢er
were sampled at 15 kHz and ¢ltered at 5 kHz by low-pass ¢lter (LPF-
100, Warner Instruments), digitized and stored on a 486PC hard disk
for further analysis. The pCLAMP 6.0 (Axon Instruments) software
package was used to generate voltage-clamp commands, acquire mem-
brane currents and analyze digitized data. All experimental data were
¢rst analyzed with Clamp¢t 6.0 and exported to Sigma Plot 5.0 for
subsequent analysis, curve ¢tting and display. 1.0 Wg/Wl (290 WM)
stock solution of BTK-2 was made in 0.1 mg/ml BSA solution with
10 mM HEPES bu¡er (pH 7.6) and was added to the ‘bath’ in cu-
mulative fashion. All electrophysiological experiments were performed
at room temperature.
2.6. Homology modeling
The primary structure of the toxin BTK-2 as obtained from the
N-terminal sequencing was aligned using the multiple sequence align-
ment program CLUSTAL W. The alignment was done on the basis of
the conserved cysteine residues. The algorithm used was BLASTP and
the scoring was done using the BLOSUM62 matrices. We used Swiss
PDB Modeler to generate the three-dimensional model of the toxin. It
was developed by substituting its residues in the known three-dimen-
sional structure of the toxin BmP02 with PDB code 1DU9. This
model was then subjected to checking, using WHAT IF [16] and the
PROCHECK [17] programs. Four C-terminal amino acids GKKD
were added to the model structure obtained from Swiss PDB modeler
using Insight II (MSI) and the structure was further energy-minimized
using Discover and Builder module, until the root mean square de-
rivatives became less than 1033 kcal/mol.
3. Results
3.1. Puri¢cation
The fractionation of the crude venom was done on a cation
exchange Resource S column, which divided the mixture into
nine fractions (S1^S9) as shown in Fig. 1A. The fractions were
separated on the basis of their basicity and the less basic
fraction S3 was further puri¢ed on a C4 HPLC reverse-phase
column as shown in Fig. 1B. The fraction eluting at 9.8 min
was collected and was ¢nally puri¢ed by passing it through
C18 HPLC column. The peptide eluted at 11.5 min was
named BTK-2 as in Fig. 1C. The molecular weight of the
toxin was found to be 3452 Da as shown in Fig. 2. The
primary amino acid sequence of BTK-2 was determined by
Edman degradation and the positions of the amino acids were
unequivocally assigned. The cysteine positions were con¢rmed
by sequencing the reduced and alkylated toxin. The primary
structure of the toxin shows 32 amino acid residues with six




with a calculated molecular weight of 3450 Da.
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3.2. Structural analysis
Fig. 3 shows the multiple sequence alignment based on the
conserved cysteines and other conserved N and C terminal
residues using CLUSTAL W. The three conserved disul¢de
bonds between Cys3^Cys19, Cys6^Cys24 and Cys10^Cys26
were determined with the help of homology. The toxin
BTK-2 shows homology to the K-KTX family of toxins,
which are known to block the potassium channel. It shows
highest similarity to leiuropeptides LpI, LpII and LpIII
(78.6%, 42.3% and 42.3%, respectively) from Leiurus quinques-
triatus hebraeus [18], BmP01, BmP02 and BmP03 (42.3%,
75.0% and 71.4%, respectively) from Buthus martensii [19],
Bs5 (71.4%) from Buthus eupeus [20] and P01 (75.0%) from
Androctonus mauretanicus mauretanicus [21].
The three-dimensional structure of several scorpion Kþ
channel blockers has been determined by NMR (nuclear mag-
netic resonance) spectroscopy, such as KTx [22], IbTx [23],
ChTx [24], MgTx [25], NTx [11]. The data reveal that all these
toxins are made up of one L-sheet linked with an K-helix by
disul¢de bridges. The helical part of these toxins includes a
Cys-X-X-X-Cys pattern with both the cysteines forming disul-
¢de bonds with the Cys-X-Cys sequence in the L-sheet. This
Fig. 1. Puri¢cation of the crude venom. A: The crude venom was applied on an ion exchange Resource S (1 ml) column. The fractionation
was done using a linear gradient of 0^0.5 M NaCl in 20 mM sodium acetate bu¡er, pH 5, with a £ow rate of 0.5 ml/min. The mixture was di-
vided into nine fractions (S1^S9). B: The S3 fraction was further puri¢ed by passing on a reverse-phase C4 column. The elution was done us-
ing a linear gradient of 0.1% TFA in acetonitrile starting from 15% for the ¢rst 5 min, 15^60% in the next 45 min, 60^100% in the next 5 min
and 100^0% in the next 5 min. The £ow rate was 2.5 ml/min and the absorbance was measured at 215 and 280 nm. The fractions were col-
lected manually as per the absorbance and retention time. C: The labeled fraction obtained from the C4 column was ¢nally puri¢ed by passing
it on a C18 reverse-phase column. The ¢nal fraction, named BTK-2, was isolated using a linear gradient starting from 15% of 0.1% TFA in
acetonitrile for the ¢rst 5 min and then going from 15 to 31% in the next 20 min, with a £ow rate of 2.5 ml/min.
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arrangement helps in bringing the speci¢c residues in juxtapo-
sition to each other and is involved in binding the toxin to the
channel protein [26]. The presence of a similar motif and high
sequence similarity of the toxin BTK-2 with the above-de-
scribed Kþ channel blockers increases the probability of this
toxin adapting a similar fold. Therefore this toxin was mod-
eled using the three-dimensional structure of BmP02 (PDB:
1DU9). This model provides an insight into understanding the
structure^function relationship of BTK-2 peptide based on its
preliminary structure. Comparison of the structure of BmP02
with the model structure of BTK-2 shows a similar backbone
structure as depicted in Fig. 4, with Cys6-His9 forming the
K-helix and the two L-strands formed by residues Pro17 to
Glu20 and Val23 to Cys26, connected by a L-turn.
3.3. hKv1.1 blockage studies
Potassium channels are among the molecular targets of
scorpion toxins. Sequentially BTK-2 belongs to the ninth sub-
family of scorpion toxins (Fig. 3) that a¡ects potassium chan-
nels. This suggests a similar pharmacological identity for
BTK-2. The e¡ect of pharmacological screening of BTK-2
peptide on human Kþ channels was performed using the Xe-
nopus oocyte system for heterologous channel expression, and
standard two-electrode voltage-clamp setup for Kþ current
recording (see Section 2). Oocytes from X. laevis expressing
either human Kv1.1 or hKv1.4 were voltage-clamped at 370
mV and stepped to a range of test potentials. Outward cur-
rents were seen on depolarizing to potentials less negative
than 340 mV shown in Fig. 5A. Application of BTK-2 to
these oocytes resulted in reduction of hKv1.1 currents as in
Fig. 5B, but had no e¡ect on hKv1.4 currents (data not
shown). Fig. 5C shows the concentration dependence of block
by BTK-2 on currents monitored at 320 mV. These data have
been analyzed in Fig. 5E to yield a half-maximal block at 4.6
WM. Washing out the toxin over a period of 15 min resulted in
negligible recovery of the current (Fig. 5A, trace labeled
wash). This is in keeping with block of Kþ channels by other
toxins such as IbTx and ScyTx [27], which is usually irrevers-
ible, and in contrast to block by agents such as 4-amino pyr-
idine (4-AP) or tetraethylammonium (TEA), which is essen-
tially completely reversible.
hKv1.1 is a voltage-dependent channel and the currents
observed are non-Ohmic due to channel opening on depolar-
ization. The blocker, however, is e¡ective at all potentials
tested shown in Fig. 5A,D, and has no signi¢cant e¡ect on
the kinetics of activation (data not shown). Further, the se-
lectivity of the channel, as estimated from the reversal of tail
currents, is unperturbed (data not shown). BTK-2 thus ap-
pears to have all the characteristics of a simple pore blocker
as reported for other scorpion toxins.
4. Discussion
In this study we have identi¢ed and characterized a new
potassium channel inhibitor from B. tamulus. The puri¢ed
toxin BTK-2 was found to be a single polypeptide chain of
Fig. 2. Mass spectra of the toxin BTK-2. The molecular mass was
determined by ESI-MS. The x and y axes show mass-to-charge ratio
(m/z) and TIC, respectively.
Fig. 3. Multiple sequence alignment of known scorpion toxins with
BTK-2. The primary sequence of the toxin BTK-2 was aligned with
other known scorpion toxins using CLUSTAL W. The alignment is
based on the conserved cysteine residues and a few other amino
acid residues. The sequences showing homology are as follows: LpI,
LpII and LpIII leiuropeptide from L. quinquestriatus hebraeus [18],
BmP01, BmP02 and BmP03 from B. martensii [19], Bs5 from B. eu-
peus [20], P01 from A. mauretanicus mauretanicus [21]. The disul¢de
bonds are shown by the straight lines connecting two cysteine resi-
dues. The region showing K-helix and two L-strands is shown by
the symbols.
Fig. 4. Molecular modeling for BTK-2 toxin. The PDB ¢le 1DU9
for the known structure of the toxin BmP02 was downloaded from
the structural database. The three-dimensional structure of BTK-2
was modeled with the help of the Swiss PDB modeler. The structure
was visualized using InsightII. The structure shows the presence of
one K-helix, two L-strands and three conserved disul¢de bonds.
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32 amino acid residues, with a molecular weight of 3452 Da.
The toxin shows 40^70% similarity to other short scorpion
toxins belonging to the K-KTx family of toxins that block
the potassium ion channel. It shows highest similarity to the
toxins belonging to the ninth subfamily of the potassium
channel blockers. The amino acid mutation is seen mainly
in the C-terminus of the toxins between 20 and 32 amino
acid residues. Although the overall fold of the scorpion toxins
is similar, there are subtle variations among them in terms of
their amino acid sequence, the size of the L-sheet, the type of
L-turn and/or the type of helix (i.e. K-helix vs. 310 helix).
These variations result in the sub-type speci¢cities of scorpion
toxins towards di¡erent Kþ channels [28], i.e. a given toxin
usually blocks only one type of Kþ channel such as Kv1.1
without a¡ecting very closely related channels such as Kv1.2
or Kv1.4. The utility of this speci¢city for the scorpion may lie
in it having to use less venom for the job, for the researcher in
using these bioactive peptides for neuro-pharmacological dis-
section of physiological processes and for the drug designer in
providing templates that may lead to speci¢c blockers. There
is variability in the ion channel in terms of the key residues,
which are present in the K-subunit that forms the tetrameric
Kþ channels [29]. The toxin BTK-2 is a blocker of the Kv1.1
channel. The classi¢cation of the toxin in the ninth subfamily
Fig. 5. hKv1.1 blockage by BTK-2 toxin. A: Currents elicited in a Xenopus oocyte expressing the hKv1.1 channel. Oocyte was held at 370
mV and stepped to the depolarizing potentials indicated against the current traces, using a pulse protocol shown in the inset to panel B. B:
The e¡ect of 6 WM BTK-2 on the Kv1.1 currents. C: An aqueous stock solution of BTK-2 (290 WM) was applied in a cumulative fashion to
the oocyte and the currents were recorded at di¡erent concentrations of BTK-2 in the bath as indicated against the traces. In order to achieve
a binding equilibrium, the Kþ currents were recorded 15 min after the addition of BTK-2 to the bath. The ‘wash’-labeled trace indicates the
currents 15 min after the manual washing of the clamped oocyte with V5 ml of the recording solution. D: Current^voltage relationship (I^V
curves) for hKv1.1 in the presence of various concentrations of BTK-2, unblocked control (b) ; 0.15 WM (9) ; 2.0 WM (F); 3.8 WM (7) ; 4.9
WM (R) ; 5.5 WM (a) ; and 6.1 WM (S). Membrane was held at 370 mV before stepping to various depolarizing potentials as described in pan-
el A. E: The concentration dependence of BTK-2 block of hKv1.1 current at a test potential of 320 mV. The normalized currents at this po-
tential were plotted as a function of BTK-2 concentration in the bath. The data points were ¢tted to a sigmoidal function (solid line). The
half-maximal e¡ect of BTK-2 was observed at 4.6 WM (dotted lines).
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of the K-KTx family is controversial as the members of this
subfamily, BmP02, BmP03 from B. martensii and LpI from
L. quinquestriatus hebraeus are known to be either non-toxic
or weakly toxic to the apamin-sensitive calcium-activated po-
tassium channel. The toxin also shows similarity to the ¢fth-
family toxins, which are potent blockers of the apamin-sensi-
tive potassium channel and include toxins like Leiurotoxin 1
from L. quinquestriatus, PO5 from A. mauretanicus maureta-
nicus. PO5, a 31 residue polypeptide cross-linked by three
disul¢de bridges [30], also possesses binding and physiological
properties similar to those of the bee venom toxin apamin (18
residue, two disul¢des). The similarity between the two toxins
lies only in the Arg-Arg-Cys-Gln motif, which is located on
the K-helix. The conformation of PO5 includes two and a half
turns of K-helix (residues 5^14) connected by a turn to the
L-sheet, which has two antiparallel strands (sequences 17^22
and 25^29). The three functionally important arginine resi-
dues, Arg6, Arg7, and Arg13 as judged by Kþ-channel block-
age studies, are all located on the solvent exposed part of the
helix and form a positively charged surface, which includes
Gln9. The presence of His31 together with the presence of the
C-terminal carboxyl amidation is necessary to obtain the irre-
versibility of the PO5^NH2 binding [31]. This residue is re-
mote from the positively charged surface, thus suggesting a
multipoint interaction of PO5^NH2 with the receptor. The
C-terminal analysis of the toxin BTK-2 shows that it does
not have the C-terminus amidated as the rest of the ¢fth-
family members which shows a⁄nity towards the apamin-sen-
sitive calcium-activated potassium channel. PO5 replacement
of the two Arg6 and Arg7 by Lys induces a 10-fold decrease
in the activity and is reduced to almost nil when replaced by
Leu [32]. Arg13 is also found to be involved in the binding
activity. The electrostatic potential is highly asymmetric and
the greatest positive potential is centered on Gln9. This sub-
family is di¡erent from that of charybdotoxin in the presence
of the functionally important residues which are present in the
helix, unlike the ChTx where they are present in the L-sheet.
BmPO2 is a 28 amino acid residue peptide and is a weak
blocker of apamin-sensitive calcium-dependent Kþ channel
with its K/L fold largely distorted. The K-helix is shortened
to one turn and the loop connecting the helix to the ¢rst
L-strand exhibits conformational heterogeneity. The instabil-
ity of BmPO2 could be attributed to the presence of a proline
in the 17th position, which is usually a glycine [33]. Since the
residue at this position makes intense contact with the K-helix,
it is supposed that the bulky side chain of proline pushes the
helix away from the L-sheet. This has a signi¢cant in£uence
on the structure and function of BmPO2, as the K-helix gets
rotated by about 40‡ to avoid Pro17 while forming the two
disul¢des with the second L-strand. The rotation further
causes both ends of the helix to unwind due to covalent re-
strictions. According to its structure, BmPO2 was supposed to
interact with its target via the side chain of Lys11 and Lys 13.
The two arginines located in the beginning of the helix in
PO5, which are believed to be involved in binding to Kþ
channels, are replaced by two acidic amino acids in both
PO1 and BmPO2. This is the major cause of the decrease in
the a⁄nity of these toxins towards the apamin-sensitive cal-
cium-activated Kþ channel. The relatively weak toxicity of
BmPO2 must also be associated with the instability of the
binding region centered at Lys11 and Lys13.
The sequence of the isolated toxin BTK-2 shows conserved
cysteine residues such as that found in the potassium channel
blockers. The other conserved residues are the same as those
present in the ninth subfamily of potassium channel-inhibiting
toxins. This peptide also shows the presence of two prolines at
the same positions as above (7 and 17), which again might
lead to an unstable K-helix conformation. The toxicity for this
toxin is di¡erent from that possessed by the other members of
its family. It has Lys11 and Lys13, but the presence of Glu in
the fourth position reduces the binding a⁄nity of the toxin to
the ion channels. The binding a⁄nity towards hKv1.1 is ac-
counted for by the presence of Lys25, which might be exposed
to the solvent surface and thus binds to the potassium chan-
nel. Kaliotoxin, however, binds to both the calcium-activated
channel as well as the voltage-gated potassium channels just
like charybdotoxin but with opposite a⁄nities. It shows very
high a⁄nity for the voltage-gated potassium channel. The
toxins having proline in the helical region are found to exhibit
a high blockage of the voltage-dependent potassium channel
[22]. The toxin BTK-2 possesses a high positive charge (+3),
which gives an indication of this peptide to be toxic. The
exposure of Lys25 might be more in BTK-2 according to
this hypothesis, as it also has a proline in its helical region
and hence we can predict this to be the main reason for the
blockage of the hKv1.1 channel.
The toxin blocks hKv1.1 with half-maximal e⁄ciency at 4.6
WM (Fig. 5). The currents observed in the presence of the
toxin have the same properties as unperturbed hKv1.1 in
terms of activation kinetics and ionic selectivity. The toxin
thus appears to have the hallmarks of a pore blocker. The
a⁄nity of BTK-2 for hKv1.1 is in the micromolar range, as
opposed to the nanomolar a⁄nities of other scorpion toxins
such as ChTx, IbTx and MgTx for their cognate channels.
However, this may be contrasted with the millimolar a⁄nities
of blockers such as 4AP and TEA. Moreover, the o¡-rates for
the binding reaction are slow for BTK-2 hKv1.1, as demon-
strated by the negligible extent of washout in 15 min. Both
4AP and TEA can be completely washed out in this time
frame. Finally, the lack of interaction with hKv1.4 is indica-
tive of speci¢c interactions with amino acid residues at the
mouth of the hKv1.1 pore.
In contrast to BTK-2, its structural relatives block slow-
conductance calcium-gated Kþ (SK) channels and not Kv
channels [26,29]. Further mutational and structural studies
on BTK-2 are required to ¢nd out the residues involved in
the speci¢city of the toxin towards the hKv1.1 channel and
therefore, the toxin could be used to analyze the architectural
di¡erences between the outer mouth of SK and Kv channel
pores. The toxin could also be used as a molecular caliper to
explore the topology of the pore region of voltage-gated po-
tassium channels as reported in the case of Kv1.3 [34].
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